Ymmunobio is proud to announce our ASCO publication on YB-800

We are thrilled to announce that Ymmunobio's abstract has been published in the American Society of Clinical Oncology (ASCO) annual conference publications:

"YB-800, a monoclonal antibody targeting the human neuronal pentraxin receptor (NPTXR), as a potential candidate for the design of a first-in-class antibody-drug conjugate (ADC) as a novel therapeutic intervention in gastro-intestinal cancers"

The full publication can be found here.

The abstract highlights using a fully humanized monoclonal antibody, YB-800, directed against the human neuronal pentraxin receptor (NPTXR). The expression of NPTXR has been associated with disease progression in several GI Cancers, including gastric, esophageal, colorectal, pancreatic, bladder and liver as well as breast and thyroid cancer. These findings provided a strong rationale for the design of a YB-800 based ADC, offering a novel therapeutic intervention option for patients with high unmet medical needs.

We are thrilled to contribute to the advancement of cancer treatment and dedicated to pursuing innovative therapies that can significantly impact patient care.